Related Experiment Videos
Should hemoglobin be normalized in patients with chronic kidney disease?
Lesley Stevens1, Caroline Stigant, Adeera Levin
1Department of Medicine, Nephrology Division, University of British Columbia, Vancouver, British Columbia, Canada.
Seminars in Dialysis
|March 5, 2002
Summary
Anemia treatment in kidney disease improves patient function, but optimal hemoglobin targets remain debated. Individualizing treatment and early intervention are crucial for managing anemia in chronic kidney disease (CKD).
Area of Science:
- Nephrology
- Hematology
- Internal Medicine
Background:
- Anemia significantly impacts patients with chronic kidney disease (CKD), affecting their overall function.
- While anemia therapy offers benefits, optimal hemoglobin targets are debated in pre-dialysis and dialysis populations.
Purpose of the Study:
- To review clinical data and physiologic concepts surrounding anemia treatment in CKD.
- To discuss individualizing hemoglobin targets and early anemia detection in kidney disease patients.
- To support current guidelines and encourage critical evaluation of anemia management practices.
Main Methods:
- Review of clinical data and physiologic principles related to anemia in CKD.
- Analysis of current guidelines from KDOQI, European Working Group, and Canadian Society of Nephrology.
- Discussion of the economic impact of anemia therapies like erythropoietin and iron supplementation.
Main Results:
- Anemia therapy can correct symptoms compromising patient function.
- Controversy persists regarding optimal hemoglobin targets for CKD patients.
- Individualized treatment and early intervention are essential for effective anemia management.
Conclusions:
- Anemia management in CKD is evolving and essential for patient care.
- Optimal outcomes require addressing hemodynamic and metabolic abnormalities alongside anemia.
- Further evaluation of current hemoglobin targets is needed based on new evidence and physiologic principles.